Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotime-Nasdaq's best kept secret? -- Ignore unavailable to you. Want to Upgrade?

To: Bill Wexler who wrote (706)	2/16/1998 4:12:00 PM
From: Jim Roof	Read Replies (1) \| Respond to of 1432

Let me see now - you are saying that a company with no sales and no earnings and a 200,000,000 market cap is a sure loser. I guess by that same standard Vical Pharmaceuticals is another one of your shorts? It is not disputed that Biotime has no sales - that takes no brains. It is not disputed that they therefore have no earnings - again you qualify for making that statement - that's another no brainer. Now we get to the crux of your argument... "Doubts from numerous experts in the field the (sic) Hextend deserves premium pricing, and near certainty that Hextend will not replace/compete with albumin". Suddenly that vagueries appear again. Name your experts, their credentials and their findings please. BTW, I do not think that BTIM is planning on competing head-to-head with albumin (which is rarely used anyway). I have read some 'expert' opinions on Hextend but they are also full of emotion and actually use the clinically scientific phrase 'that's bullshit' when asked of Hextend will be better than Hespan - that's science... ? The experts at Biotime have sunk a lot of cash into their own stock, have yet to sell a share, continue to accumulate (remember the filing about a week or so ago) and continue to have the support of Abbott with both Hextend and now with Pentalyte. Can we at least agree that the success of BTIM is not in your sentiment nor mine but rather in the efficacy of their lead product? If we can do that then we can meaningfully discuss what the FUTURE holds for sales and earnings. You know as well as I that the current stock price is forward-looking (what stock is not?) and that all hinges upon FDA approval (a cinch) and the marketing and manufacturing by Abbott leading to sales. So, in a conciliatory tone, I look forward to hearing truly empirical data and interpretation of the Phase III trials that stands up to scrutiny that you may have to offer to support your position that BTIM will soon be a one dollar stock still languishing with no sales and no earnings. As for me, I am looking at a stock that was about 2 a share that is now 17 - not one that was 27 and is now 17. I have a good gain and am content to play this one out. Jim